2.13 -0.15 (-6.58%) | 02-12 17:44 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 3.07 | 1-year : | 3.69 |
Resists | First : | 2.63 | Second : | 3.16 |
Pivot price | 2.27 ![]() |
|||
Supports | First : | 1.76 | Second : | 1.47 |
MAs | MA(5) : | 2.25 ![]() |
MA(20) : | 2.36 ![]() |
MA(100) : | 2.78 ![]() |
MA(250) : | 3.81 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 38.6 ![]() |
D(3) : | 36.8 ![]() |
RSI | RSI(14): 42 ![]() |
|||
52-week | High : | 5.94 | Low : | 1.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ INTS ] has closed above bottom band by 6.9%. Bollinger Bands are 56.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 2.4 - 2.42 | 2.42 - 2.43 |
Low: | 1.82 - 1.83 | 1.83 - 1.84 |
Close: | 2.11 - 2.13 | 2.13 - 2.15 |
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Tue, 28 Jan 2025
Major Breakthrough: Advanced Cancer Trial Clears Critical Safety Milestone for Revolutionary Treatment - StockTitan
Fri, 10 Jan 2025
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 - PR Newswire
Thu, 21 Nov 2024
Shelton-based Intensity Therapeutics gains $3M investment - Hartford Business Journal
Thu, 21 Nov 2024
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - PR Newswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 15 (M) |
Shares Float | 6 (M) |
Held by Insiders | 47.1 (%) |
Held by Institutions | 12.4 (%) |
Shares Short | 44 (K) |
Shares Short P.Month | 30 (K) |
EPS | -1.08 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.95 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -72.8 % |
Return on Equity (ttm) | -147.3 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -15 (M) |
Levered Free Cash Flow | 10 (M) |
PE Ratio | -2 |
PEG Ratio | 0 |
Price to Book value | 2.21 |
Price to Sales | 0 |
Price to Cash Flow | -2.2 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |